

Stat3 Regulates Liver Progenitor Cell-Driven Liver Regeneration in Zebrafish

Mehwish Khaliq,* Sungjin Ko,* Yinzi Liu,† Hualin Wang,‡ Yonghua Sun,‡
Lila Solnica-Krezel,† and Donghun Shin*

*Department of Developmental Biology, McGowan Institute for Regenerative Medicine, Pittsburgh Liver Research Center,
University of Pittsburgh, Pittsburgh, PA, USA

†Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA

‡China Zebrafish Resource Center, State Key Laboratory of Freshwater Ecology and Biotechnology, Institute of Hydrobiology,
Chinese Academy of Sciences, Wuhan, P.R. China

After liver injury, regeneration manifests as either (1) hepatocytes proliferating to restore the lost hepatocyte mass or (2) if hepatocyte proliferation is compromised, biliary epithelial cells (BECs) dedifferentiating into liver progenitor cells (LPCs), which subsequently differentiate into hepatocytes. Following pharmacogenetic ablation of hepatocytes in *Tg(fabp10a:CFP-NTR)* zebrafish, resulting in severe liver injury, signal transducer and activator of transcription 3 (Stat3) and its target gene and negative regulator, *socs3a*, were upregulated in regenerating livers. Using either Stat3 inhibitors, JSI-124 and S3I-201, or *stat3* zebrafish mutants, we investigated the role of Stat3 in LPC-driven liver regeneration. Although Stat3 suppression reduced the size of regenerating livers, BEC dedifferentiation into LPCs was unaffected. However, regenerating livers displayed a delay in LPC-to-hepatocyte differentiation and a significant reduction in the number of BECs. While no difference in cell death was detected, Stat3 inhibition significantly reduced LPC proliferation. Notably, *stat3* mutants phenocopied the effects of Stat3 chemical inhibitors, although the mutant phenotype was incompletely penetrant. Intriguingly, a subset of *socs3a* mutants also displayed a lower number of BECs in regenerating livers. We conclude that the Stat3/Socs3a pathway is necessary for the proper timing of LPC-to-hepatocyte differentiation and establishing the proper number of BECs during LPC-driven liver regeneration.

Key words: Liver progenitor cells (LPCs); Biliary epithelial cells (BECs); Oval cells; Socs3

INTRODUCTION

With the story of an eagle picking at Prometheus' liver daily, the Ancient Greeks first alluded to the remarkable ability of the liver to regenerate. To date, no true stem cell population has been identified in the liver. Instead, extensive studies have revealed two main modes of liver regeneration depending on the severity of liver injury: (1) hepatocyte driven and (2) biliary epithelial cell (BEC) driven. Typically following liver injury, hepatocytes proliferate to restore the lost liver mass^{1,2}. However, if hepatocyte proliferation is blocked, then BECs undergo dedifferentiation into hepatoblast-like cells (HB-LCs), also termed liver progenitor cells (LPCs)³ or oval cells. LPCs are bipotent⁴, facultative resident stem progenitor cells that can differentiate into either hepatocytes or BECs to restore the lost liver mass⁴⁻⁶.

Moreover, LPCs observed in a zebrafish LPC-driven liver regeneration model^{7,8} share similar characteristics

with BEC-derived oval cells or ductular reactions observed in both rodent liver injury models⁹ and human severe acute or chronic liver injury conditions¹⁰. Currently, chronic liver diseases, including cirrhosis, are the 12th leading cause of death in the US¹¹. Although liver transplantation offers an effective therapy, more than 50% of patients on the transplant waiting list do not receive a donor liver transplant in time¹². The presence of LPCs can be double edged. Following severe liver injury, the bipotent LPCs, activated via BEC dedifferentiation, are needed to replenish the functional cells (i.e., hepatocytes) in the liver¹³. However, the continued presence of LPCs can be detrimental. In one study, in patients presenting with chronic liver disease, such as alcoholic hepatitis, LPC markers were increased and correlated with short-term mortality and disease severity¹⁴. In a separate study, the number of LPCs, detected in various liver diseases including non-alcoholic fatty liver disease, correlates with

Address correspondence to Donghun Shin, Department of Developmental Biology, McGowan Institute for Regenerative Medicine, Pittsburgh Liver Research Center, University of Pittsburgh, 3501 5th Avenue #5063, Pittsburgh, PA 15260, USA. Tel: 1-412-624-2144; Fax: 1-412-383-2211; E-mail: donghuns@pitt.edu

disease severity¹⁵⁻¹⁷. Furthermore, hepatocellular carcinoma liver cells expressing OV6, an LPC marker, have been linked to tumor progression due to the invasive/tumorigenic properties of OV6⁺ cells¹⁸. Thus, the continued presence of LPCs is undesirable and can be detrimental to functional liver recovery; however, if the LPCs can be coaxed to differentiate into hepatocytes, then generating more LPCs can prove beneficial for the innate regenerative process. Because of the shortage of donor livers and the implications of LPCs in disease progression, an essential step in treating liver disease and augmenting the innate regenerative process is a better understanding of the underlying mediators and mechanisms of LPC-driven liver regeneration, including LPC activation, proliferation, and differentiation.

With that goal in mind, our lab⁷ and others^{8,19} have previously reported on a zebrafish model, in which following near-complete hepatocyte ablation, BECs extensively contribute to hepatocytes by giving rise to LPCs. This phenomenon is not zebrafish exclusive, however, as the BEC-to-hepatocyte-mediated regeneration was similarly observed in several mouse models in which hepatocyte proliferation is greatly compromised^{16,20}.

A separate model of LPC-mediated repair in mice is the choline-deficient, ethionine-supplemented (CDE) diet; mice fed a CDE diet display an increased release of cytokines, such as interleukin-6 (IL-6), after liver injury²¹. Once IL-6 binds to its cognate receptor and coreceptor, gp130-associated Janus tyrosine kinases (JAKs) are autophosphorylated and subsequently activated. JAKs can then phosphorylate transcription factors, such as signal transducer and activator (STAT) 3, which dimerize and are able to translocate to the nucleus, inducing the expression of downstream target genes^{22,23}.

Previous reports have considered the involvement of Stat3 in hepatocyte-driven regeneration²⁴ and suggested its role in oval cell proliferation²⁵. In the partial hepatectomy (PHx) model of murine liver injury, *Stat3* deficiency led to an increased mortality rate and slightly decreased hepatocyte proliferation²⁴. In the CDE diet model of liver injury, *Stat3* expression was upregulated in the oval cell population with high proliferative potential²⁵. In addition, mice with a hepatocyte-specific knockout of suppressor of cytokine signaling 3 (*Socs3*), a negative regulator of STAT3²⁶, display STAT3 hyperactivation after PHx, which results in enhanced proliferation during regeneration²⁷. Given the known involvement of *Stat3* in hepatocyte survival and proliferation after liver injury, we hypothesized that in zebrafish, Stat3, along with *Socs3*, may also regulate LPC-driven liver regeneration.

Here using the zebrafish hepatocyte ablation model for LPC-driven liver regeneration, we report on the roles of Stat3 in LPC proliferation and LPC-to-hepatocyte differentiation during the regeneration. We investigated the

roles of Stat3 and *Socs3a* in LPC-driven liver regeneration by two methods: (1) utilizing a JAK-specific inhibitor as well as a Stat3 dimerization inhibitor to block Stat3 downstream signaling and (2) utilizing zebrafish *stat3* and *socs3a* mutants generated by genome editing technology. Our findings show that Stat3 plays an important role in regulating LPC proliferation as well as LPC differentiation into hepatocytes during LPC-driven liver regeneration. Moreover, Stat3 and *Socs3a* are important for regulating the proper number of BECs during the regeneration process.

MATERIALS AND METHODS

Zebrafish Maintenance

Embryos and adult zebrafish (*Danio rerio*) were raised and maintained under standard laboratory conditions²⁸ with protocols approved by the University of Pittsburgh Institutional Animal Care and Use Committee. We used *stat3*^{stl27 29} and *socs3a*^{ihb31} mutants and the following transgenic lines: *Tg(fabp10a:DsRed,ela3l:GFP)*^{sz12 30} [referred to as *Tg(fabp10a:DsRed)*], *Tg(EPV:Tp1-Mmu.Hbb:Venus-Mmu.Odc1)*^{sz40 31} [referred to as *Tg(Tp1:VenusPEST)*], *Tg(EPV:Tp1-Mmu.Hbb:hist2h21-mCherry)*^{sz39 31} [referred to as *Tg(Tp1:H2B-mCherry)*], *Tg(fabp10a:CFP-NTR)*^{sz31 32}, and *Tg(fabp10a:mAGFP-gmnn,cryaa:ECFP)*^{pf608 33} [referred to as *Tg(fabp10a:mAGFP-gmnn)*].

Genotyping of the stat3^{stl27} Mutant Line

The wild-type allele was amplified by PCR with a forward primer 5'-CCTCCACAGGACATGGAG-3' and a common reverse primer 5'-ATATTGTGGAACCCCTGACCAAAAACAACATTTCCAATGCAGTCATACCTCCAGCACTC-3'. The mutant allele was separately amplified with a forward primer 5'-CATCCTCCACAGGACAGA-3' and the common reverse primer. While the wild-type allele generated a 139-bp band, the mutant allele generated a 135-bp band.

Generation of the socs3a Mutant Line

The construction of sequence-specific transcription activator-like effector nuclease (TALEN) effector repeats recognizing two targeting sites on exon 2 of *socs3a* (left: ACCACTTCAAGACCT and right: GCACCAGCTGAAACT) was performed using the unit assembly method as previously described³⁴. To generate capped mRNA containing DNA-binding TALEN repeats and the *FokI* endonuclease domain, the TALEN expression vectors were linearized with *NotI* and transcribed using a Sp6 mRNA kit (Message Machine Kit; AM1340; Ambion). Capped mRNA was diluted to 200 ng/μl and injected into wild-type embryos at the one-cell stage. A primer pair [*socs3a*, TACTCATCCTGACTTTTCTC (forward) and CCAGTCTCAGCACGCAGT (reverse)] was used to amplify the target region; the PCR products were digested

with *StyI* restriction enzyme. The remaining mutation-positive larvae were raised to F0 adulthood and outcrossed with wild-type adults. The genomic DNA of F1 larvae was subject to PCR amplification, *StyI* digestion, and Sanger sequencing. The F1 population containing *socs3a* heterozygous larvae were raised to adulthood and genotyped. The *socs3a* mutant line with a 61-bp deletion from 221 to 281 bp of the wild-type *socs3a* coding sequence was established and is available at the China Zebrafish Resource Center.

Hepatocyte Ablation and Chemical Inhibitor Treatments

To ablate hepatocytes, *Tg(fabp10a:CFP-NTR)* larvae were treated with 10 mM metronidazole (Mtz) in egg water supplemented with 0.2% dimethyl sulfoxide (DMSO) and 0.2 mM 1-phenyl-2-thiourea (PTU) as previously described³⁵. For Stat3 inhibitor experiments, larvae were treated with 7 μ M JSI-124 (also known as Cucurbitacin I; Cayman Chemical, Ann Arbor, MI, USA) or 200 μ M S3I-201 (Sigma-Aldrich, St. Louis, MO, USA). Larvae were treated with JSI-124 or S3I-201 from ablation 0 h (A0h) or A18h to regeneration 24 h (R24h) or R48h.

Zebrafish Whole-Mount In Situ Hybridization (WISH), qPCR, and Immunostaining

Whole-mount in situ hybridization was performed as previously described³⁶. *socs3a* forward primer (5'-AAG ACCTTCAGCTCCAAGGTG-3') and reverse primer (5'-GTGTGTCCGTTACAGTCTTCT-3') were used to amplify the *socs3a* region for in situ probes; the *stat3* plasmid used for this PCR was a gift from Ken Poss at Duke University. For qPCR analysis, 100 livers were dissected for each condition, and total RNA was extracted using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). The SuperScript III First-Strand Synthesis SuperMix (Life Technologies, Grand Island, NY, USA) was used to synthesize cDNA from the extracted RNA. Using the Bio-Rad iQ5 PCR machine with iQ SYBR Green Supermix (Bio-Rad, Hercules, CA, USA), qPCR was performed as previously described³⁷. *eef1b2* was used for normalization. The primers used for qPCR analysis were *eef1b2* (forward: 5'-CCCTCTCAGGCTGATATTGC-3'; reverse: 5'-TAAGCTGCAAGCCTCTCCTC-3'), *socs3a* (forward: 5'-CACTAACTTCTCTAAAGCAGGG-3'; reverse: 5'-GGTCTTGAAGTGGTAAAACG-3'), and *stat3* (forward: 5'-GGACTTCCCGGACAGTGAG-3'; reverse: 5'-ATCGCTTGTGTTGCCAGAG-3'). Whole-mount immunostaining was performed as previously described³² using the following antibodies: goat anti-Hnf4a (1:70; Santa Cruz, Dallas, TX, USA), mouse monoclonal anti-Bhmt (1:400; a gift from J. Peng, Zhejiang University, P.R. China), mouse monoclonal anti-Alcam (1:10; ZIRC; Eugene, OR, USA), rabbit polyclonal anti-Abcb11

(1:500; PC-064; Kamiya Biomedical, Seattle, WA, USA), and Alexa Fluor 488-, 568-, and 647-conjugated secondary antibodies (1:300; Life Technologies).

TUNEL and EdU Assays

Apoptotic cell death was analyzed according to the protocol of the In Situ Cell Death Detection Kit, TMR Red (Roche, Switzerland). Following whole-mount immunostaining, terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) labeling was applied. Cell proliferation was performed using the protocol outlined in the Click-iT EdU Alexa Fluor 647 Imaging Kit (Life Technologies). Larvae were treated with egg water supplemented with 0.2 mM PTU containing 50 mM EdU and 5% DMSO at R0h or R18h. After a 6-h treatment window, larvae were harvested at R6h or R24h, respectively, and fixed in fresh 3% formaldehyde overnight at 4°C. After fixation, samples were prepared for subsequent imaging and statistical analysis.

BODIPY C5 Lipid Analog Assay

A 2-h treatment of 0.5 μ M BODIPY C5 (Life Technologies)³⁸ was used to assess ductal morphology and morphogenesis in regenerating livers. Following BODIPY C5 treatment, larvae were rinsed briefly and anesthetized with 0.016% tricaine in egg water supplemented with 0.2 mM PTU and mounted in 1% low-melting agarose for confocal imaging.

Image Acquisition, Processing, and Statistical Analysis

Zeiss LSM700 and Leica M205 FA were used for confocal microscopy and epifluorescence microscopy, respectively. ZEN 2009 software was used to assemble and analyze confocal images. Leica MZ16 stereomicroscope was used to obtain in situ images. Adobe Illustrator and Photoshop were used for assembling figures, schematics, and labels. GraphPad Prism 7 software was used to create and assemble quantitative data. Quantification for liver size, fluorescence, and cell counting was performed using the NIH ImageJ software. Unpaired two-tailed Student's *t*-tests were used for most statistical analyses; for comparisons across >2 groups, one-way ANOVA was used. A value of $p < 0.05$ was considered statistically significant. Quantitative data are shown as means \pm standard error of the mean (SEM).

RESULTS

Stat3 Inhibition Impairs LPC-Driven Liver Regeneration

We⁷ and others^{8,19} have previously characterized a zebrafish LPC-driven liver regeneration model where upon extensive hepatocyte ablation, BECs contribute to the repopulation of the liver. We utilized *Tg(fabp10a:CFP-NTR)* transgenic fish, which express the bacterial

nitroreductase (NTR) enzyme fused with the cyan fluorescent protein (CFP) under the hepatocyte-specific, *fabp10a*, promoter⁷. Upon treatment of a nontoxic pro-drug, Mtz, cells expressing NTR metabolize Mtz into a cytotoxic agent, inducing DNA interstrand cross-links and subsequent cell death specifically in NTR-expressing cells³⁹. Since NTR-expressing hepatocytes undergo genetic-based apoptosis and can no longer contribute to the regenerative response, BECs contribute to liver regeneration in a multistep process. Initially, nearly all BECs dedifferentiate into HB-LCs, also termed LPCs, which strongly express *Hnf4a* (a hepatoblast/hepatocyte marker) and *Prox1* (a hepatoblast/hepatocyte/BEC marker) in *Alcam*⁺ (a BEC marker) BEC-derived cells. Next, the LPCs proliferate and differentiate into either hepatocytes or BECs, concluding with the proliferation of the newly generated hepatocytes and BECs and the restoration of the lost liver mass. Using this model, we explored the implications of inflammatory signaling, specifically focusing on Stat3 and *Socs3a*, in LPC-driven liver regeneration.

To induce hepatocyte ablation, *fabp10a*:CFP-NTR⁺ larvae were treated with Mtz from 3.5 to 5 days postfertilization (dpf). Following this 36-h treatment period (ablation; A36h), Mtz washout was considered as the initiation of regeneration (R0h). Based on our previously reported RNAseq analysis⁴⁰, we found that *stat3* and its negative feedback regulator, *socs3a*, were expressed in regenerating livers at R6h (Fig. 1A), which was confirmed by qPCR (Fig. 1B) and in situ hybridization (Fig. 1C, arrows). Since *Socs3* is a direct target gene of Stat3⁴¹, upregulation of *socs3a* in the regenerating livers (Fig. 1B) suggests active Stat3 signaling during the regeneration.

To elucidate the role of Stat3 in LPC-driven liver regeneration, we utilized a JAK-specific kinase inhibitor, JSI-124, that blocks Stat3 activation⁴². JSI-124 has previously been used in zebrafish to block Stat3 signaling^{43,44}. We first assessed the effect of chemically inhibiting Stat3 activation on liver size. To visualize the liver size in our regeneration setting, we utilized the *Tg(fabp10a:DsRed)* line that expresses DsRed in hepatocytes. Stat3 was inhibited from either A0h (at the start of Mtz treatment)




Figure 1. Signal transducer and activator of transcription 3 (Stat3) inhibition impairs liver progenitor cell (LPC)-driven liver regeneration. (A) RNaseq data showing the expression levels of *stat3* and *socs3a* in control 5 days postfertilization (dpf), ablated A18h, and regenerating R6h, R12h, and R24h livers. Their expression levels are shown in numbers indicating FPKM standing for fragments per kilobase of exon per million fragments mapped. (B) qPCR quantification showing the relative mRNA expression levels of *stat3* and *socs3a* between nonablated 5 dpf and metronidazole (Mtz)-ablated R6h livers. (C) Whole-mount in situ hybridization (WISH) reveals *stat3* and *socs3a* expression in nonablated 5-dpf livers (dashed lines) and Mtz-treated R6h livers (arrows). Lateral view, anterior to the left. (D) Epifluorescence images showing *fabp10a*:DsRed expression (red) in regenerating livers treated with dimethyl sulfoxide (DMSO) or JSI-124. Quantification of *fabp10a*:DsRed expression per liver area is shown. Total cell fluorescence (A.U., arbitrary units) considers both area of the liver and the fluorescence intensity. Scale bars: 100 μ m; error bars: \pm standard error of the mean (SEM).

to R24h, A18h to R24h, or R0h to R24h, at which time the liver size was examined. JSI-124 treatment significantly reduced the liver size at R24h from both the A0h and A18h, but not R0h, treatment (Fig. 1D), suggesting a positive role of Stat3 signaling during an earlier phase of LPC-driven liver regeneration, prior to R0h.

Stat3 Inhibition Reduces Liver Size Due to an LPC Proliferation Defect in Regenerating Livers

LPC-driven liver regeneration comprises three main steps: (1) BEC dedifferentiation into LPCs, (2) LPC proliferation, and (3) LPC-to-hepatocyte differentiation. First, we investigated the effect of Stat3 inhibition on BEC dedifferentiation. To mark BECs and BEC-derived cells, we used the *Tg(Tp1:H2B-mCherry)* line that expresses H2B-mCherry fusion proteins driven by the *Tp1* promoter containing Notch response elements⁴⁵. In the zebrafish liver, Notch activity is exclusively observed in BECs, and the prolonged stability of H2B-mCherry allows for marking BEC-derived cells even after Notch signaling is turned off. To inspect BEC dedifferentiation into LPCs, we examined the induction of Hnf4a in BECs or BEC-derived cells at R6h, indicative of BEC dedifferentiation. Typically, in the LPC-driven liver regeneration model, Hnf4a induction in BECs begins around A30h–A33h⁴⁰, and by R6h, the *Tp1:H2B-mCherry*⁺ cells are referred to as LPCs or BEC-derived cells. Interestingly, in A0h–R6h JSI-124-treated larvae, the induction of Hnf4a in *Tp1:H2B-mCherry*⁺ cells (BEC-derived cells) was comparable to DMSO-treated control regenerating livers (Fig. 2A). These data indicate that BEC dedifferentiation in regenerating livers is unaffected by Stat3 inhibition.

Next, we investigated whether the smaller liver size was due to a defect in LPC proliferation or cell death. To assess the first, we used the 5-ethynyl-2'-deoxyuridine (EdU) labeling and the cell cycle reporter line *Tg(fabp10a:mAGFP-gmnn)*³³. Based on the cell cycle oscillator phenomenon of Geminin proteins⁴⁶, this transgenic line only labels hepatocytes in the S/G₂/M phases of the cell cycle. In our zebrafish liver regeneration studies, this line labels proliferating LPCs at R6h³³. Since we observed a gross phenotype at R24h (i.e., smaller liver size) following JSI-124 treatment from A0h to R24h, we hypothesized that any proliferation or cell death defect would occur prior to R24h. Following this logic, we conducted our EdU and transgenic cell cycle assays at R6h and R24h. Compared to control regenerating livers, JSI-124-treated regenerating livers displayed a significant decrease in LPC proliferation at R6h (Fig. 2B and C), but not at R24h (data not shown), indicative of a transient reduction in LPC proliferation.

Using the TUNEL assay, we assessed cell death in regenerating livers at R6h. Unlike the cell proliferation defect,

there was no significant difference in TUNEL/*Tp1:H2B-mCherry* double-positive cells between control and JSI-124-treated regenerating livers (Fig. 2D). These data provide evidence that the smaller liver size is not due to an increase in cell death, but rather a defect in proliferation.

Stat3 Inhibition Temporarily Delays LPC-to-Hepatocyte Differentiation in Regenerating Livers

To examine the effect of Stat3 inhibition on LPC-to-hepatocyte differentiation, we used betaine-homocysteine S-methyltransferase (Bhmt) antibodies to mark newly generated hepatocytes⁴⁰. At R6h, upon Stat3 inhibition, Bhmt expression was visibly reduced in 77% of the regenerating livers, indicative of an LPC-to-hepatocyte differentiation defect (Fig. 3A). Interestingly, this LPC-to-hepatocyte differentiation defect was temporary, as at a later stage, such as R24h, Bhmt expression in JSI-124-treated livers was comparable to that in control livers (Fig. 3B). These data indicate that Stat3 inhibition blocks LPC-to-hepatocyte differentiation; however, since Bhmt expression recovers by R24h, this blockage is transient. In addition to its role in mediating LPC proliferation, Stat3 also regulates the proper timing of LPC-to-hepatocyte differentiation.

Stat3-Inhibited Regenerating Livers Contain Reduced BEC Numbers and Display Aberrant Intrahepatic Biliary Structure

In addition to the delayed differentiation of LPCs into hepatocytes in Stat3-inhibited livers, we observed a lower number of BECs in JSI-124-treated regenerating livers than in control regenerating livers, as assessed by *Tp1:H2B-mCherry* expression (Fig. 4A). In addition to the H2B-mCherry expression, we used another BEC marker, Alcam⁴⁷, to clearly reveal BECs at R24h (Fig. 4A). Unlike the hepatocyte differentiation defect, which was temporary, the BEC number per liver area in JSI-124-treated regenerating livers remained low even later, such as R54h (Fig. 4B).

We further examined the impact of delayed LPC-to-hepatocyte differentiation and reduced BEC number by investigating hepatocyte polarity and biliary morphogenesis. Typically expressed on the apical side of the hepatocyte membrane, the bile salt export pump marker, ATP-binding cassette subfamily B member 11 (Abcb11), marks bile canaliculi in hepatocytes^{48,49}. The number of Abcb11⁺ cells per liver area was significantly decreased in JSI-124-treated livers compared to DMSO-treated controls (Fig. 4B). We confirmed the Abcb11 phenotype with the BODIPY C5 lipid analog assay, which allows for the visualization of the intrahepatic biliary network as the processed lipids pass through the biliary conduits³⁸. Compared to the control regenerating livers, JSI-124-treated regenerating livers had shorter and round-shaped




Figure 2. Stat3 inhibition reduces liver size due to an LPC proliferation defect in regenerating livers. (A) Confocal projection images showing the expression of *Tp1:VenusPEST* (green), *Tp1:H2B-mCherry* (red), and Hnf4a (gray) in regenerating livers at R6h. Quantification of the percentage of Hnf4a⁺ cells among biliary epithelial cell (BEC)-derived cells (H2B-mCherry⁺ cells) in regenerating livers is shown. (B) Confocal projection images showing *Tp1:H2B-mCherry* (red) expression and EdU (green) staining in regenerating livers at R6h. Quantification of the percentage of EdU⁺ cells among *Tp1:H2B-mCherry*⁺ cells (arrows) in the liver is shown. Numbers in the top left corner indicate the proportion of livers exhibiting the representative phenotype at R6h. (C) Confocal projection images showing *Tp1:H2B-mCherry* (red) and *fabp10a:mAGFP-gmnn* (gray) expression in regenerating livers at R6h. Quantification of the percentage of mAGFP-gmnn⁺ cells among *Tp1:H2B-mCherry*⁺ cells is shown. (D) Confocal projection images showing *Tp1:H2B-mCherry* (red) expression and terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL; green) staining (arrows) in regenerating livers at R6h. Quantification of the total number of TUNEL⁺ cells per liver at R6h is shown. Dashed lines outline regenerating livers. Scale bars: 20 μ m; error bars: \pm SEM.




Figure 3. Stat3 inhibition temporarily delays LPC-to-hepatocyte differentiation in regenerating livers. (A) Confocal projection images showing *Tp1:H2B-mCherry* (red) and *Bhmt* (gray) expression in regenerating livers at R6h. Quantification of the percentage of *Bhmt*⁺ cells among BEC-derived cells in the regenerating livers is shown. (B) Confocal projection images showing *Tp1:H2B-mCherry* (red) and *Bhmt* (gray) expression in regenerating livers at R24h. The number of JSI-124-treated larvae exhibiting the representative phenotype shown at R24h is shown in the upper left corner. Dashed lines outline regenerating livers. Scale bars: 20 μ m; error bars: \pm SEM.

bile canaliculi (Fig. 4C, arrowheads) and reduced density of biliary conduits (Fig. 4C, cartoons). JSI-124 treatment in nonablated control livers, however, had no effect on liver morphology or BEC number (Fig. 4D), suggesting the regeneration-restricted role of Stat3 in the zebrafish liver.

We further validated the effect of blocking Stat3 using a different inhibitor, S3I-201, which blocks Stat3 dimerization and subsequent Stat3 activation⁵⁰. Similar to the JSI-124 liver phenotypes, S3I-201-treated larvae also exhibited a significantly smaller regenerating liver size at R24h (Fig. 5A), a delay in LPC-to-hepatocyte differentiation at R6h (Fig. 5B), and a reduced BEC number at R24h (Fig. 5C). Altogether, these data implicate Stat3 as an important regulator in the timing for LPC-to-hepatocyte differentiation and in the establishment of a proper BEC population during LPC-driven liver regeneration.

A Subset of stat3 Homozygous Mutants Exhibit Fewer BECs and a Delay in LPC-to-Hepatocyte Differentiation During LPC-Driven Liver Regeneration

To determine whether *stat3* mutants phenocopied the aberrant liver regeneration phenotypes observed in JSI-124-treated larvae, we examined LPC-driven liver regeneration in *stat3*^{-/-} mutants²⁹, focusing on three main phenotypes: (1) LPC-to-hepatocyte differentiation, (2) BEC number, and (3) LPC proliferation. First, similar to the JSI-124-treated larvae, *stat3*^{-/-} mutants exhibited reduced

Bhmt expression at R6h (Fig. 6A), indicative of an initial defect in LPC-to-hepatocyte differentiation. However, only ~55% of *stat3*^{-/-} mutants ($n=9$) exhibited decreased *Bhmt* expression. The other 45% of *stat3*^{-/-} mutants showed no significant difference in *Bhmt* expression compared to wild-type larvae. Moreover, as in the JSI-124-treated livers, hepatocyte differentiation is not completely blocked but rather delayed as *Bhmt* expression at R24h was unaffected between wild-type and *stat3*^{-/-} mutants (Fig. 6B).

At R24h, ~35% of the *stat3*^{-/-} mutants ($n=14$) exhibited a low BEC number in the regenerating livers (Fig. 6B). Moreover, a significant decrease in the percentage of *EdU/Tp1:H2B-mCherry* double-positive cells was observed at R6h in a subset (37%; $n=8$) of *stat3*^{-/-} mutants, indicating an LPC proliferation defect (Fig. 6C). Altogether, data from *stat3* mutant analyses suggest that *stat3* partially regulates LPC proliferation and LPC-to-hepatocyte differentiation during LPC-driven liver regeneration.

socs3a Homozygous Mutants Exhibit a Mild but Significant Defect in BEC Number During LPC-Driven Liver Regeneration

Since *Socs3a* acts as a downstream negative regulator of the Stat3 signaling pathway⁵¹, we speculated that absence of *socs3a* would allow us to study the effects of Stat3 hyperactivation on LPC-driven liver regeneration.




Figure 4. Stat3-inhibited livers maintain low BEC numbers and display aberrant intrahepatic biliary structure. (A) Confocal projection images showing *Tp1:H2B-mCherry* (red) and *Alcam* (green) expression in regenerating livers at R24h. Quantification of the number of BECs (*Alcam*/*H2B-mCherry* double-positive cells) per liver is shown. For the count of BECs, the total number of BECs in the whole liver is divided by the liver area. Arrows point to weak *H2B-mCherry*⁺/*Alcam*⁺ cells, which were more prevalent in JSI-124-treated livers compared to controls. (B) Confocal projection images of regenerating livers at R54h showing *Tp1:H2B-mCherry* (red) and *Abcb11* (green) expression. Quantification of the number of BECs (*H2B-mCherry*⁺ cells) and bile canaliculi per liver area is shown. (C) Confocal projection images showing BODIPY C5 staining (green) and *Tp1:H2B-mCherry* expression (red) at R54h. Inset boxes show a magnified image of the selected area. Arrows point to bile ductules; arrowheads point to bile canaliculi. (D) Confocal projection images showing the expression of *Tp1:H2B-mCherry* (red), *Tp1:VenusPEST* (green), *fabp10a:CFP-NTR* (blue), and *Alcam* (gray) in nonablated livers treated with DMSO or JSI-124. Quantification of the number of BECs (*Alcam*⁺/*H2B-mCherry*⁺ cells) per liver is shown. Dashed lines outline regenerating livers. Scale bars: 20 μ m; error bars: \pm SEM.

Using TALEN genome editing technology, we generated *socs3a* mutants with a 61-base deletion. The *socs3a* mutant larvae exhibited no liver developmental defects and grew normally to adults. Interestingly, as assessed by *Bhmt* expression, LPC-to-hepatocyte differentiation was affected in $\sim 30\%$ of *socs3a*^{-/-} mutants ($n=22$) at R6h (Fig. 7A), but not affected at all at R24h (Fig. 7B). In

addition, the mutant regenerating livers had a significant decrease in BEC number compared to wild type at R24h (Fig. 7C). Altogether, our data from *socs3a* mutant analyses suggest that similar to *Stat3*, *Socs3a* also partially controls LPC-to-hepatocyte differentiation and establishment of a proper BEC population during LPC-driven liver regeneration.




Figure 5. Stat3 inhibition by S3I-201 impairs LPC-driven liver regeneration. (A) Epifluorescence images showing *fabp10a*:DsRed expression (red) in the regenerating livers treated with DMSO or S3I-201 at the indicated time points. Quantification of *fabp10a*:DsRed expression per liver area is shown. Total cell fluorescence considers both area of the liver and the fluorescence intensity. (B) Confocal projection images showing *Tp1*:H2B-mCherry (red) and *Bhmt* (gray) expression in regenerating livers at R6h. Quantification of the percentage of *Bhmt*⁺ cells among BEC-derived cells is shown. (C) Confocal projection images showing the expression of *Tp1*:VenusPEST (green), *Tp1*:H2B-mCherry (red), and *Alcam* (gray) in regenerating livers at R24h. Quantification of the number of BECs (*H2B-mCherry*⁺ cells) per liver area is shown. Dashed lines outline regenerating livers. Scale bars: 100 μ m (A), 20 μ m (B, C); error bars: \pm SEM.

DISCUSSION

The signaling pathways regulating LPC proliferation and differentiation during LPC-driven liver regeneration remain poorly understood. In this study, we sought to determine the role of Stat3 in LPC-driven liver regeneration by modulating Stat3 signaling using chemical inhibitors, JSI-124 and S3I-201, as well as *stat3* and *socs3a*

mutants. Chemically inhibiting Stat3 significantly reduced the size of regenerating livers at R24h. To elucidate the process of LPC-driven liver regeneration affected by Stat3 inhibition, we examined (1) BEC dedifferentiation, (2) LPC proliferation, and (3) LPC differentiation into hepatocytes. First, we found that BEC dedifferentiation during liver regeneration was unaffected in JSI-124-treated livers. We further noted that Stat3 inhibition decreased the




Figure 6. A subset of *stat3* homozygous mutants exhibit reduced number of BECs and a delay in LPC-to-hepatocyte differentiation during LPC-driven liver regeneration. (A) Confocal projection images showing *Tp1:H2B-mCherry* (red) and *Bhmt* (gray) expression in regenerating livers of wild-type or *stat3* homozygous mutants at R6h. Quantification of the percentage of *Bhmt*⁺ cells among *H2B-mCherry*⁺ cells is shown. The proportion of regenerating livers exhibiting the *Bhmt* phenotype in *stat3* mutants is shown in the top left corner. Arrows point to *Bhmt*⁺ and *H2B-mCherry*⁺ cells. Arrowheads point to *Bhmt*⁻ and *H2B-mCherry*⁺ cells. (B) Confocal projection images showing *Tp1:H2B-mCherry* (red) and *Bhmt* (gray) expression at R24h in wild-type and *stat3* mutants. Quantification of the number of strong *H2B-mCherry*⁺ cells per liver area is shown. The proportion of *stat3*^{-/-} mutants exhibiting the reduced BEC number phenotype is shown in the upper left corner. (C) Confocal projection images showing *Tp1:H2B-mCherry* (red) expression and EdU (gray) staining in regenerating R6h livers of wild-type and *stat3*^{-/-} mutants. Numbers in the top left corner indicate the proportion of *stat3* mutant livers exhibiting reduced proliferation ($n = 3/8$) versus nonaffected *stat3* mutants ($n = 5/8$) compared to wild-type larvae. Quantification of the percentage of EdU⁺ cells among *H2B-mCherry*⁺ cells in the regenerating liver is shown. Arrows point to EdU/*H2B-mCherry* double-positive cells; dashed lines outline regenerating livers. Scale bars: 20 μ m; error bars: \pm SEM.

number of BECs in regenerating livers at R24h, and this decrease was still maintained later at R54h. Additionally, our data revealed that during liver regeneration, in *Stat3* inhibitor-treated animals, livers exhibited a decrease in LPC proliferation at R6h, but not at R24h, which helps to explain the decreased liver size at R24h and recovery

of the liver size at later time points. Last, *Stat3* inhibition resulted in a delay in LPC-to-hepatocyte differentiation during LPC-driven liver regeneration.

Given no current marker that can clearly distinguish between LPCs and BECs, we utilized the induction of *fabp10a:rasGFP* in BECs to show that nearly all BECs




Figure 7. *socs3a* homozygous mutants exhibit a mild but significant defect in BEC number during LPC-driven liver regeneration. (A) Confocal projection images showing *Tp1*:H2B-mCherry (red) and *Bhmt* (gray) expression in the regenerating livers of wild-type and *socs3a* mutants at R6h. Numbers in the top right corner indicate the proportion of *socs3a* mutants exhibiting a reduced number of BECs at R6h ($n=6/22$). Quantification of the percentage of *Bhmt*⁺ cells among H2B-mCherry⁺ cells is shown. Arrows point to *Bhmt*⁺ and H2B-mCherry⁺ cells. Arrowheads point to *Bhmt*⁻ and H2B-mCherry⁺ cells. (B) Confocal projection images of wild-type and *socs3a* mutant regenerating livers exhibiting *Tp1*:H2B-mCherry (red) and *Bhmt* (gray) expression at R24h. (C) Confocal projection images showing *Tp1*:H2B-mCherry (red) and *Alcam* (green) expression in the regenerating livers of wild-type and *socs3a* mutants at R24h. Quantification of the number of BECs (H2B-mCherry/*Alcam* double-positive cells) per liver area is shown. Arrows point to H2B-mCherry/*Alcam* double-positive cells. Dashed lines outline regenerating livers. Scale bars: 20 μ m; error bars: \pm SEM.

dedifferentiate into LPCs in the zebrafish hepatocyte ablation model⁴⁰. Since the induction of *Hnf4a* in BECs/BEC-derived cells, which was used as a marker for BEC dedifferentiation, was found to be comparable between DMSO- and JSI-124-treated larvae, we concluded that BEC dedifferentiation is not affected upon *Stat3* loss. Thus, since BEC dedifferentiation is occurring as expected, we can speculate that the reduced BEC number in the JSI-124-treated larvae at R24h is not due to a BEC dedifferentiation defect. Instead, it is more likely due to both the reduced LPC-to-BEC differentiation and reduced LPC

proliferation. This reduction in BEC number may also affect the proper formation of intrahepatic bile ducts later, such as at R54h.

In our zebrafish LPC-driven liver regeneration model, *stat3* was expressed in regenerating livers during the early phases of liver regeneration (R6h), when the regenerating liver predominantly consists of LPCs. In the 2-AAF/PHx rat model of oval cell activation, in which 2-acetylaminofluorene (2-AAF) is administered prior to PHx to block hepatocyte proliferation, *Stat3* was highly upregulated in the oval cell population that correlated with the highest

proliferative potential²⁵. Depending on the cell type and injury stimulus, Stat3 plays a critical role in several biological processes, including proliferation, apoptosis, and inflammation. Previous studies have implicated Stat3 in the regulation of myogenic differentiation in skeletal muscles. During muscle repair, *Stat3* activation in satellite cells drives these muscle stem cells to choose differentiation over self-renewal^{52,53}, which partly supports a delayed LPC-to-hepatocyte differentiation in Stat3-inhibited regenerating livers. In a separate study of two mouse models, a muscle satellite cell (MuSC)-specific *Stat3* knockout and *Stat3*/dystrophin double knockout, cell proliferation of the MuSCs was decreased⁵⁴. This supports our finding that inhibition of Stat3 resulted in a proliferation defect in LPCs at R6h during LPC-driven liver regeneration. Therefore, we can speculate that the smaller liver size at R24h is a result of the lower number of LPCs established at R6h, resulting in a subsequent lower number of LPCs available for hepatocyte differentiation.

Several mouse studies have also examined the role of Stat3 in liver regeneration. For example, following PHx in liver-specific *Stat3* knockout mice, the mortality rate was significantly increased during liver regeneration²⁴. This increase was speculated to be due to a defect in the Stat3-dependent acute phase response; this response is activated following liver injury and involves the induction of survival-related proteins^{55,56}. In a separate model of liver injury (i.e., CCl₄), although liver-specific *Stat3* knockout mice had a slight decrease in hepatocyte proliferation, they displayed no difference in survival or necrosis compared to wild-type littermates²⁴.

In our LPC-driven liver regeneration model, we discovered a reduction in Bhmt expression in a majority of JSI-124-treated regenerating livers at R6h, which indicates an LPC-to-hepatocyte differentiation defect. However, at R24h, no difference was observed in Bhmt expression between control and JSI-124-treated regenerating livers, indicating a delay in hepatocyte differentiation rather than a complete blockage. Possibly, Stat3 is one of several important regulators implicated in hepatocyte differentiation; hence, upon Stat3 inhibition, other compensatory mechanisms may be activated to counteract the Stat3 deficiency. Such a phenomenon was detected in liver-specific *Stat3* knockout mice: STAT1, which is minimally expressed in noninjured livers, had increased expression levels following PHx⁵⁷. Moreover, we observed that both *stat3* knockout and Stat3 hyperactivation (*socs3a* knockout) conditions in zebrafish displayed similar phenotypes in LPC-driven liver regeneration, including delayed LPC differentiation. We propose that perturbations that disturb the optimal level of Stat3 activity, either through reduction (*stat3* mutant) or through enhancement (*socs3a* mutant), can lead to similar defects. Such a phenomenon,

where loss of function and overexpression of a particular gene exhibit identical phenotypes, has been observed in multiple proteins, including SPT5⁵⁸. In addition, perturbation, via knockout or overexpression, of the kinase SRPK1, a downstream target of AKT, was found to have the same tumorigenic phenotype in mouse embryonic fibroblasts⁵⁹.

Moreover, data from our *stat3* and *socs3a* mutant analyses suggest that *stat3* and *socs3a* only partially recapitulate the phenotypes observed in Stat3 chemically inhibited livers. One possibility is that since complete loss of a gene's function can prove harmful for the organism, cells may offset a permanent, genetic loss of a gene with compensatory mechanisms, which are not employed upon temporary chemical inhibition. A similar occurrence of incomplete phenotypic reproducibility between temporary versus genetic/permanent inhibition of a gene's function is seen in morpholino versus genetic knockouts⁶⁰. Second, although JSI-124 blocks Stat3 signaling, it does so by targeting the upstream activator of Stat3, namely, JAK kinases. In contrast, in the *stat3* mutants, *stat3* expression is lost by direct, targeted mutation at the *stat3* locus. Because of the temporary, acute, and indirect nature of Stat3 inhibition in JSI-124-treated larvae, compared to the permanent, genetic, and direct loss of Stat3 in mutants, the chemically treated cells may not have employed adequate counterbalancing measures to compensate for the loss of an important signaling pathway (i.e., Stat3).

Although we did not address the upstream activators or downstream mediators of the Stat3 signaling pathway, future studies can focus on identifying these factors and their role in LPC proliferation and differentiation. Factors such as the IL cytokines may be important activators of the Stat3/Socs3 pathway during LPC-driven liver regeneration. In particular, in the CDE diet-fed mouse model of liver injury and oval cell activation, IL-6 levels were upregulated, and IL-6 knockout mice displayed a reduction in total oval cell numbers²¹. Moreover, when CDE diet-fed mice were stimulated with IL-6, *Socs3* expression was increased in the LPCs²¹, raising a possibility that IL-6 or its homolog may be the upstream activator of Stat3 signaling during LPC-driven liver regeneration.

ACKNOWLEDGMENTS: We thank Jinrong Peng for the anti-Bhmt antibody, Ken Poss for the *stat3* in situ probe, and Neil Hukriede and Michael Tsang for the discussions. This work was supported by grants from the NIH to D.S. (DK101426), M.K. (F31DK105714), and L.S.K. (R35GM118179), and from the Chinese Academy of Sciences and National Natural Science Foundation of China to Y.S. (31671501). This work was funded by NIH grants to D.S. (R01DK101426), L.S.K. (R35GM118179), and M.K. (F31DK105714) and by the Chinese Academy of Sciences and National Natural Science Foundation of China to Y.S. (31671501). The authors declare no conflicts of interest.

REFERENCES

1. Michalopoulos GK, DeFrances MC. Liver regeneration. *Science* 1997;276(5309):60–6.
2. Michalopoulos GK. Liver regeneration. *J Cell Physiol*. 2007;213(2):286–300.
3. Miyajima A, Tanaka M, Itoh T. Stem/progenitor cells in liver development, homeostasis, regeneration, and reprogramming. *Cell Stem Cell* 2014;14(5):561–74.
4. Okabe M, Tsukahara Y, Tanaka M, Suzuki K, Saito S, Kamiya Y, Tsujimura T, Nakamura K, Miyajima A. Potential hepatic stem cells reside in EpCAM+ cells of normal and injured mouse liver. *Development* 2009;136(11):1951–60.
5. Paku S, Schnur J, Nagy P, Thorgeirsson SS. Origin and structural evolution of the early proliferating oval cells in rat liver. *Am J Pathol*. 2001;158(4):1313–23.
6. Lu WY, Bird TG, Boulter L, Tsuchiya A, Cole AM, Hay T, Guest RV, Wojtacha D, Man TY, Mackinnon A, and others. Hepatic progenitor cells of biliary origin with liver repopulation capacity. *Nat Cell Biol*. 2015;17(8):971–83.
7. Choi TY, Ninov N, Stainier DY, Shin D. Extensive conversion of hepatic biliary epithelial cells to hepatocytes after near total loss of hepatocytes in zebrafish. *Gastroenterology* 2014;146(3):776–88.
8. He J, Lu H, Zou Q, Luo L. Regeneration of liver after extreme hepatocyte loss occurs mainly via biliary transdifferentiation in zebrafish. *Gastroenterology* 2014;146(3):789–800 e8.
9. Tarlow BD, Pelz C, Naugler WE, Wakefield L, Wilson EM, Finegold MJ, Grompe M. Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. *Cell Stem Cell* 2014;15(5):605–18.
10. Stueck AE, Wanless IR. Hepatocyte buds derived from progenitor cells repopulate regions of parenchymal extinction in human cirrhosis. *Hepatology* 2015;61(5):1696–707.
11. Kochanek KD, Murphy SL, Xu JQ, B T-V. Deaths: Final data for 2014. *National Vital Statistics Reports: National Center for Health Statistics*; 2016.
12. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2012 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration; 2014.
13. Weng HL, Cai X, Yuan X, Liebe R, Dooley S, Li H, Wang TL. Two sides of one coin: Massive hepatic necrosis and progenitor cell-mediated regeneration in acute liver failure. *Front Physiol*. 2015;6:178.
14. Sancho-Bru P, Altamirano J, Rodrigo-Torres D, Coll M, Millán C, José Lozano J, Miquel R, Arroyo V, Caballería J, Ginès P, and others. Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. *Hepatology* 2012;55(6):1931–41.
15. Nobili V, Carpino G, Alisi A, Franchitto A, Alpini G, De Vito R, Onori P, Alvaro D, Gaudio E. Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. *Hepatology* 2012;56(6):2142–53.
16. Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson JR. Fibrosis correlates with a ductular reaction in hepatitis C: Roles of impaired replication, progenitor cells and steatosis. *Hepatology* 2005;41(4):809–18.
17. Lowes KN, Brennan BA, Yeoh GC, Olynyk JK. Oval cell numbers in human chronic liver diseases are directly related to disease severity. *Am J Pathol*. 1999;154(2):537–41.
18. Yang W, Wang C, Lin Y, Liu Q, Yu LX, Tang L, Yan HX, Fu J, Chen Y, Zhang HL, and others. OV6⁺ tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma. *J Hepatol*. 2012;57(3):613–20.
19. Huang M, Chang A, Choi M, Zhou D, Anania FA, Shin CH. Antagonistic interaction between Wnt and Notch activity modulates the regenerative capacity of a zebrafish fibrotic liver model. *Hepatology* 2014;60(5):1753–66.
20. Raven A, Lu WY, Man TY, Ferreira-Gonzalez S, O’Duibhir E, Dwyer BJ, Thomson JP, Meehan RR, Bogorad R, Koteliensky V, and others. Cholangiocytes act as facultative liver stem cells during impaired hepatocyte regeneration. *Nature* 2017;547(7663):350–4.
21. Yeoh GC, Ernst M, Rose-John S, Akhurst B, Payne C, Long S, Alexander W, Croker B, Grail D, Matthews VB. Opposing roles of gp130-mediated STAT-3 and ERK-1/2 signaling in liver progenitor cell migration and proliferation. *Hepatology* 2007;45(2):486–94.
22. Hemmann U, Gerhartz C, Heesel B, Sasse J, Kurapkat G, Grötzinger J, Wollmer A, Zhong Z, Darnell JE, Graeve L, and others. Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation. *J Biol Chem*. 1996;271(22):12999–3007.
23. Zhong Z, Wen Z, Darnell JE. Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. *Science* 1994;264(5155):95–8.
24. Moh A, Iwamoto Y, Chai GX, Zhang SS, Kano A, Yang DD, Zhang W, Wang J, Jacoby JJ, Gao B, and others. Role of STAT3 in liver regeneration: Survival, DNA synthesis, inflammatory reaction and liver mass recovery. *Lab Invest*. 2007;87(10):1018–28.
25. Sánchez A, Factor VM, Schroeder IS, Nagy P, Thorgeirsson SS. Activation of NF-kappaB and STAT3 in rat oval cells during 2-acetylaminofluorene/partial hepatectomy-induced liver regeneration. *Hepatology* 2004;39(2):376–85.
26. Sasaki A, Yasukawa H, Suzuki A, Kamizono S, Syoda T, Kinjo I, Sasaki M, Johnston JA, Yoshimura A. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. *Genes Cells* 1999;4(6):339–51.
27. Riehle KJ, Campbell JS, McMahan RS, Johnson MM, Beyer RP, Bammler TK, Fausto N. Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3. *J Exp Med*. 2008;205(1):91–103.
28. Westerfield M. *The zebrafish book. A guide for the laboratory use of zebrafish (Danio rerio)*. Eugene: University of Oregon Press; 2000.
29. Liu Y, Sepich DR, Solnica-Krezel L. Stat3/Cdc25a-dependent cell proliferation promotes embryonic axis extension during zebrafish gastrulation. *PLoS Genet*. 2017;13(2):e1006564.
30. Korzh S, Pan X, Garcia-Lecea M, Winata CL, Wohland T, Korzh V, Gong Z. Requirement of vasculogenesis and blood circulation in late stages of liver growth in zebrafish. *BMC Dev Biol*. 2008;8:84.

31. Ninov N, Borius M, Stainier DYR. Different levels of Notch signaling regulate quiescence, renewal and differentiation in pancreatic endocrine progenitors. *Development* 2012;139(9):1557–67.
32. Dong PD, Munson CA, Norton W, Crosnier C, Pan X, Gong Z, Neumann CJ, Stainier DY. Fgf10 regulates hepatopancreatic ductal system patterning and differentiation. *Nat Genet.* 2007;39(3):397–402.
33. Ko S, Choi TY, Russell JO, So J, Monga SPS, Shin D. Bromodomain and extraterminal (BET) proteins regulate biliary-driven liver regeneration. *J Hepatol.* 2016;64(2):316–25.
34. Huang P, Xiao A, Zhou M, Zhu Z, Lin S, Zhang B. Heritable gene targeting in zebrafish using customized TALENs. *Nat Biotechnol.* 2011;29(8):699–700.
35. Choi TY, Khaliq M, Ko S, So J, Shin D. Hepatocyte-specific ablation in zebrafish to study biliary-driven liver regeneration. *J Vis Exp.* 2015(99):e52785.
36. Alexander J, Stainier DY, Yelon D. Screening mosaic F1 females for mutations affecting zebrafish heart induction and patterning. *Dev Genet.* 1998;22(3):288–99.
37. de Groh ED, Swanhart LM, Cosentino CC, Jackson RL, Dai W, Kitchens CA, Day BW, Smithgall TE, Hukriede NA. Inhibition of histone deacetylase expands the renal progenitor cell population. *J Am Soc Nephrol.* 2010;21(5):794–802.
38. Carten JD, Bradford MK, Farber SA. Visualizing digestive organ morphology and function using differential fatty acid metabolism in live zebrafish. *Dev Biol.* 2011;360(2):276–85.
39. Curado S, Stainier DY, Anderson RM. Nitroreductase-mediated cell/tissue ablation in zebrafish: A spatially and temporally controlled ablation method with applications in developmental and regeneration studies. *Nat Protoc.* 2008;3(6):948–54.
40. Choi TY, Khaliq M, Tsurusaki S, Ninov N, Stainier DYR, Tanaka M, Shin D. Bone morphogenetic protein signaling governs biliary-driven liver regeneration in zebrafish through *tbx2b* and *id2a*. *Hepatology* 2017;66(5):1616–30.
41. Auernhammer CJ, Bousquet C, Melmed S. Autoregulation of pituitary corticotroph SOCS-3 expression: Characterization of the murine SOCS-3 promoter. *Proc Natl Acad Sci USA* 1999;96(12):6964–9.
42. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. *Cancer Res.* 2003;63(6):1270–9.
43. Elsaiedi F, Bembem MA, Zhao XF, Goldman D. Jak/Stat signaling stimulates zebrafish optic nerve regeneration and overcomes the inhibitory actions of *Socs3* and *Sfpq*. *J Neurosci.* 2014;34(7):2632–44.
44. Zhao XF, Wan J, Powell C, Ramchandran R, Myers MG, Goldman D. Leptin and IL-6 family cytokines synergize to stimulate Müller glia reprogramming and retina regeneration. *Cell Rep.* 2014;9(1):272–84.
45. Delous M, Yin C, Shin D, Ninov N, Debrito Carten J, Pan L, Ma TP, Farber SA, Moens CB, Stainier DY. *Sox9b* is a key regulator of pancreaticobiliary ductal system development. *PLoS Genet.* 2012;8(6):e1002754.
46. Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H, Kashiwagi S, Fukami K, Miyata T, Miyoshi H, and others. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. *Cell* 2008;132(3):487–98.
47. Sakaguchi TF, Sadler KC, Crosnier C, Stainier DY. Endothelial signals modulate hepatocyte apical-basal polarization in zebrafish. *Curr Biol.* 2008;18(20):1565–71.
48. Lorent K, Moore JC, Siekmann AF, Lawson N, Pack M. Reiterative use of the notch signal during zebrafish intrahepatic biliary development. *Dev Dyn.* 2010;239(3):855–64.
49. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Hofmann AF, Meier PJ. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. *J Biol Chem.* 1998;273(16):10046–50.
50. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence NJ, and others. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. *Proc Natl Acad Sci USA* 2007;104(18):7391–6.
51. Duhé RJ, Wang LH, Farrar WL. Negative regulation of Janus kinases. *Cell Biochem Biophys.* 2001;34(1):17–59.
52. Sun L, Ma K, Wang H, Xiao F, Gao Y, Zhang W, Wang K, Gao X, Ip N, Wu Z. JAK1-STAT1-STAT3, a key pathway promoting proliferation and preventing premature differentiation of myoblasts. *J Cell Biol.* 2007;179(1):129–38.
53. Wang K, Wang C, Xiao F, Wang H, Wu Z. JAK2/STAT2/STAT3 are required for myogenic differentiation. *J Biol Chem.* 2008;283(49):34029–36.
54. Zhu H, Xiao F, Wang G, Wei X, Jiang L, Chen Y, Zhu L, Wang H, Diao Y, Ip NY, and others. STAT3 regulates self-renewal of adult muscle satellite cells during injury-induced muscle regeneration. *Cell Rep.* 2016;16(8):2102–15.
55. Akira S. Roles of STAT3 defined by tissue-specific gene targeting. *Oncogene* 2000;19(21):2607–11.
56. Alonzi T, Maritano D, Gorgoni B, Rizzuto G, Libert C, Poli V. Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver. *Mol Cell Biol.* 2001;21(5):1621–32.
57. Li W, Liang X, Kellendonk C, Poli V, Taub R. STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. *J Biol Chem.* 2002;277(32):28411–7.
58. Clark-Adams CD, Winston F. The SPT6 gene is essential for growth and is required for delta-mediated transcription in *Saccharomyces cerevisiae*. *Mol Cell Biol.* 1987;7(2):679–86.
59. Wang P, Zhou Z, Hu A, Ponte de Albuquerque C, Zhou Y, Hong L, Sierrecki E, Ajiro M, Kruhlak M, Harris C, and others. Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt. *Mol Cell* 2014;54(3):378–91.
60. Rossi A, Kontarakis Z, Gerri C, Nolte H, Hölper S, Krüger M, Stainier DY. Genetic compensation induced by deleterious mutations but not gene knockdowns. *Nature* 2015;524(7564):230–3.